Biotoxtech Co., Ltd. announced that it expects to receive KRW 12 billion in funding from KB Securities Co.,Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd.
July 01, 2024
Share
Biotoxtech Co., Ltd. announced a private placemen to issue Zero Coupon Bearer-Type, Non-Guaranteed, Non-Separable Private Placement Bonds With Warrants due July 8, 2027 for the gross proceeds of KRW 12,000,000,000 on July 2, 2024. The transaction will include participation from new investors Shinhan Investment & Securities Co., Ltd. (In the position of fiduciary of Fund 1) for KRW 900,000,000, NH Investment & Securities Co., Ltd. (In the fiduciary position of Fund 2) for KRW 550,000,000, KB Securities Co., Ltd. (In the position of trustee of Fund 3) for KRW 850,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 4) for KRW 700,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 5) for KRW1,000,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 6) for KRW 3,000,000,000, Korea Investment & Securities Co., Ltd. (In the position of trustee of Fund 7) for KRW 3,000,000,000, Korea Investment & Securities Co., Ltd. (In the fiduciary position of Fund 8) for KRW 500,000,000, Korea Investment & Securities Co., Ltd. (In the position of trustee of Fund 9) for KRW 500,000,000, Korea Investment & Securities Co., Ltd. (In the position of trustee of Fund 10) for KRW 500,000,000 and Korea Investment & Securities Co., Ltd. (In the position of trustee of Fund 11) for KRW 500,000,000. The bonds are 100% convertible into 2,373,887 shares at a fixed conversion price of KRW 5,055 from July 8, 2025 to June 8, 2027.
The bonds bear zero coupon rate, 2% maturity rate and matures on July 8, 2029. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on July 8, 2024.
Biotoxtech Co., Ltd. is a Korea-based company engaged in the research of non-clinical evaluation business. The Company provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
BIOTOXTECH CO., LTD. 
